Acute Leukemia Equipment & Supplies
123 equipment items found
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
It is described to stabilize topoisomerase I/DNA cleavable complexes and promote rapid apoptotic cell death in radiation-resistant human B-lineage acute lymphoblastic leukemia cells.http://www.creative-peptides.com/product/topotecan-hydrochloride-item-10-101-124-112.html ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TL02-59 is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM), and potently suppresses acute myelogenous leukemia (AML) cell ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
The NB-4 cell line was derived from the marrow of a patient with acute promyelocytic leukemia (APL; M3 in the FAB nomenclature) in second relapse in ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
Scope of application: Detect the expression of CD3 in human biological specimens and provide doctors with auxiliary information for diagnosis. Testable items: detection of lymphocyte subpopulations, regulatory T cells, PD-1, expressed in blast cells of acute T-ceii leukemia and tumor cells of mature T-ceii ...
Manufactured by:Wuhan HealthCare Biotechnology Co., Ltd. based inWuhan, CHINA
Translocations in bands 11q23.3-11q24 are associated with several human cancers, including acute lymphoid and acute myeloid leukemias (AML) and Ewing's sarcoma. ...
Manufactured by:DIAGNOSTIC BIOSYSTEMS INC. based inPleasanton, CALIFORNIA (USA)
CD7 is expressed by most peripheral blood T cells, NK cells, and all thymocytes. It is one of the earliest surface antigens on T and NK-cell lineages. The antibody is a useful aid for classification of T-cell malignancies ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology; Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for newly diagnosed FLT3-ITD positive AML, ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Agilent Technologies, Inc. based inSanta Clara, CALIFORNIA (USA)
The ClearSeq AML panel targets 20 genes identified by leading researchers to be frequently mutated in acute myeloid leukemia (AML). It is designed for full coverage of target regions with multiple amplicons covering each target for greater confidence in somatic variant calling. Combined with intuitive data analysis workflows in Agilent’s SureCall software, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
Scope of application: Detect the expression of CD4 in human biological specimens and provide doctors with auxiliary information for diagnosis. Testable items: Lymphocyte subpopulation detection, CD4 cell count, regulatory T cells, PD-1, blast cells of acute T lymphoblastic leukemia, tumor cells of mature T cell lymphoma, sometimes also expressed in ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
Our product production process strictly follows relevant standards and undergoes multiple rigorous tests to ensure product quality. We pay great attention to details and use a rigorous attitude to ensure the smooth progress of your experiment or detection. We promise fast supply, ensure timely delivery, and provide comprehensive pre-sales and after-sales services to meet your ...
by:Precipio, Inc based inNew Haven, CONNECTICUT (USA)
Precipio’s HemeScreen acute myeloid leukemia AML Panel offerings are in vitro diagnostic assays that screen for clinically actionable somatic mutations in targets of interest related to AML. This Research Use Only (RUO) assay is specifically designed to screen for mutations using High Resolution Melt Analysis in genes that are of clinical relevance: IDH1, ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...